Eli Lilly and Novo Nordisk — the dominant players in obesity drug development — each submitted a new weight-loss drug to the ...

Eli Lilly also said it has filed for Food and Drug Administration approval of the daily GLP-1 pill, called orforglipron, for ...

Eli Lilly seeks FDA approval for orforglipron, a once-daily pill shown in trials to help maintain weight loss after stopping ...

The average weight increase after 52 weeks for Wegovy patients was 2 pounds, whereas Zepbound patients gained 11 pounds. Eli ...

Eli Lilly reports Phase 3 data showing oral obesity drug orforglipron maintained weight loss after Wegovy or Zepbound, beating placebo.

Lilly has now submitted a new drug application (NDA) for orforglipron to the FDA for use in adults with obesity.

The pills are expected to cost much less then shots of blockbuster drugs like Zepbound and Wegovy. Mr. Funk was the managing ...

Topline results from the ATTAIN-MAINTAIN trial show that orforglipron, an investigational oral GLP-1 RA, helps people ...

Doctors and groups representing employers said they’re increasingly hearing about companies cutting weight loss drugs out of ...

Eli Lilly has shown patients maintained most of their weight loss after switching from injectable GLP-1s to its oral drug ...

Eli Lilly's oral pill helped maintain weight loss in patients switching from its GLP-1 injection, Zepbound, and rival Novo ...

Eli Lilly stock hits a 90+ Quality score. BofA calls LLY underpriced, citing major growth ahead for its oral obesity drug.